SecBot SecBot
8-K ·Filed Mar 3, 2026

KPTI

Karyopharm Therapeutics Inc.
BEARISH
Impact 8/10
Horizonweeks Processed8mo ago SEC0001503802-26-000006
8-K material event: Items 1.01
Actionable Insight ▼ Bearish

The stock is likely to face significant downward pressure as the company is in financial distress and must raise substantial capital by June 10, 2026 to avoid default. The forbearance agreement suggests creditors anticipate payment difficulties. Traders should monitor for any capital raise announcements and assess dilution risk.

DirectionBearish
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$9.13
T+0 close · Mar 3, 2026 · via day close
Latest settled
−1.64%
T+60 · $8.98
Vs SPY
−11.96%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 3 $9.13entry
  2. T+1 · 9mo ago +0.22%α −0.54% · $9.15
  3. T+5 · 8mo ago −9.86%α −9.38% · $8.23
  4. T+20 · 8mo ago −38.99%α −34.59% · $5.57
  5. T+60 · 6mo ago −1.64%α −11.96% · $8.98
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Karyopharm Therapeutics amended its credit agreement and entered into a forbearance agreement with its lenders and noteholders to defer principal and interest payments until September 2026, contingent on the company raising at least $25 million in equity financing by June 10, 2026. This restructuring indicates severe liquidity pressure and financial distress.

Key Financial Metrics

Deal Type
credit_facility

Key Facts

  • Karyopharm entered into a Second Amendment to its Credit and Guaranty Agreement to defer principal and interest payments
  • The deferral is contingent on the company raising $25 million in equity financing by June 10, 2026 (the 'Capital Raise Trigger')
  • The company also entered into a Forbearance Agreement with 100% of its lenders and noteholders
  • The forbearance covers payment defaults on convertible notes due 2028 and 2029
  • The company faces substantial doubt regarding its ability to continue as a going concern
  • The restructuring allows deferral of a June 10, 2026 principal payment and June 30, 2026 interest payment until September 2026

Financial Impact

Deferral of principal and interest payments worth tens of millions of dollars, contingent on raising $25M in equity

liquiditydebt servicegoing concern

Risk Factors

  • Failure to raise $25 million by June 10, 2026 would trigger default and potential bankruptcy
  • Any equity raise will be highly dilutive to existing shareholders
  • The company faces substantial doubt about its ability to continue as a going concern
  • Creditors could resume collection actions if the capital raise fails

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001503802-26-000006
Document: kpti-20260227.htm0001503802-26-000006
Document: 0001503802-26-000006-index-headers.html0001503802-26-000006
Document: 0001503802-26-000006-index.html0001503802-26-000006
Document: 0001503802-26-000006.txt0001503802-26-000006

US Market Status

Market Closed · Opens in 7h 51m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 3, 2026